CA2323448A1 - Methodes visant a bloquer la resorption osseuse - Google Patents

Methodes visant a bloquer la resorption osseuse Download PDF

Info

Publication number
CA2323448A1
CA2323448A1 CA002323448A CA2323448A CA2323448A1 CA 2323448 A1 CA2323448 A1 CA 2323448A1 CA 002323448 A CA002323448 A CA 002323448A CA 2323448 A CA2323448 A CA 2323448A CA 2323448 A1 CA2323448 A1 CA 2323448A1
Authority
CA
Canada
Prior art keywords
hmg
coa reductase
group
reductase inhibitor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323448A
Other languages
English (en)
Inventor
John E. Fisher
Gideon A. Rodan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809791.8A external-priority patent/GB9809791D0/en
Priority claimed from GBGB9810885.5A external-priority patent/GB9810885D0/en
Priority claimed from GBGB9822699.6A external-priority patent/GB9822699D0/en
Application filed by Individual filed Critical Individual
Publication of CA2323448A1 publication Critical patent/CA2323448A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention a trait à des méthodes visant à bloquer la résorption osseuse consistant à administrer une quantité efficace du point de vue thérapeutique d'un inhibiteur de la 3-hydroxy-3-méthylglutaryl coenzyme A réductase.
CA002323448A 1998-03-13 1999-03-09 Methodes visant a bloquer la resorption osseuse Abandoned CA2323448A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US7791398P 1998-03-13 1998-03-13
US60/077,913 1998-03-13
US7815798P 1998-03-16 1998-03-16
US60/078,157 1998-03-16
GB9809791.8 1998-05-07
GBGB9809791.8A GB9809791D0 (en) 1998-05-07 1998-05-07 Methods of inhibiting bone resorption
GB9810885.5 1998-05-20
GBGB9810885.5A GB9810885D0 (en) 1998-05-20 1998-05-20 Methods of inhibiting bone resorption
US9291898P 1998-07-15 1998-07-15
US60/092,918 1998-07-15
GB9822699.6 1998-10-16
GBGB9822699.6A GB9822699D0 (en) 1998-10-16 1998-10-16 Methods of inhibiting bone resorption
PCT/US1999/005061 WO1999045923A1 (fr) 1998-03-13 1999-03-09 Methodes visant a bloquer la resorption osseuse

Publications (1)

Publication Number Publication Date
CA2323448A1 true CA2323448A1 (fr) 1999-09-16

Family

ID=27547312

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323448A Abandoned CA2323448A1 (fr) 1998-03-13 1999-03-09 Methodes visant a bloquer la resorption osseuse

Country Status (5)

Country Link
EP (1) EP1061917A1 (fr)
JP (1) JP2002506030A (fr)
AU (1) AU2901199A (fr)
CA (1) CA2323448A1 (fr)
WO (1) WO1999045923A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
WO2001037876A2 (fr) * 1999-11-24 2001-05-31 Bayer Aktiengesellschaft Procedes d'amelioration de conditions osseuses anormales
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
JP2001253827A (ja) * 2000-02-15 2001-09-18 Pfizer Prod Inc 骨粗鬆症を治療するための組成物および方法
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
EP1291017A3 (fr) * 2001-09-10 2003-07-02 Warner-Lambert Company Utilisation de statines pour prévenir la formation d'osteoclastes
KR20030075715A (ko) * 2002-03-20 2003-09-26 학교법인 경희대학교 성장촉진활성을 갖는 로바스타틴, 이를 포함하는 약제학적조성물 및 이의 사용방법
EP1556057A4 (fr) * 2002-08-29 2009-07-15 Univ California Agents et procedes pour stimuler la formation osseuse
GB0220885D0 (en) * 2002-09-09 2002-10-16 Novartis Ag Organic compounds
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
GB0327742D0 (en) * 2003-11-28 2003-12-31 Isis Innovation Novel uses of known drugs
EP1993558B1 (fr) 2006-02-27 2014-07-30 The Regents of The University of California Composés oxystérols et hedgehog voie
AU2008331808B2 (en) 2007-03-16 2014-08-21 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
CA2872751A1 (fr) 2012-05-07 2013-11-14 The Regents Of The University Of California Oxy133, un analogue de l'oxysterol, induisant l'osteo-genese et la signalisation hedgehog et inhibant l'adipogenese
WO2014030132A2 (fr) 2012-08-22 2014-02-27 Universidad De Los Andes Utilisation de statines pour une parodontopathie et une régénération osseuse
CN105263500A (zh) 2013-05-02 2016-01-20 加利福尼亚大学董事会 骨选择性成骨性氧固醇-骨靶向剂

Also Published As

Publication number Publication date
WO1999045923A1 (fr) 1999-09-16
EP1061917A1 (fr) 2000-12-27
JP2002506030A (ja) 2002-02-26
AU2901199A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
CA2323448A1 (fr) Methodes visant a bloquer la resorption osseuse
AU757104B2 (en) Compositions and methods for inhibiting bone resorption
US5994329A (en) Method for inhibiting bone resorption
US6432932B1 (en) Method for inhibiting bone resorption
JP2001253827A (ja) 骨粗鬆症を治療するための組成物および方法
CA2294595C (fr) Inhibition de resorption osseuse
US20050261250A1 (en) Compositions and methods for inhibiting bone resorption
US20010025028A1 (en) Methods of inhibiting bone resorption
US20020004218A1 (en) Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
US20040180862A1 (en) Compositions and methods for inhibiting bone resorption
AU741818B2 (en) Method for inhibiting bone resorption
AU2002303925A1 (en) Compositions and methods for inhibiting bone resorption
CA2467715A1 (fr) Compositions et methodes pour inhiber la resorption osseuse
GB2414181A (en) compositions containing a bisphosphonate and a Vitamin D derivative
AU2001252997A1 (en) Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
CA2349733A1 (fr) Inhibition de resorption osseuse
AU2004202143A1 (en) Compositions and methods for inhibiting bone resorption

Legal Events

Date Code Title Description
FZDE Dead